Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 3 boards, counting each seat separately. Longest: Q32 Bio Inc., 3 years.
Q32 Bio Inc.
Director
Kardigan Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Q32 Bio Inc. June 14, 202392.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 1, 2026 | Takeda Pharmaceutical Company Limited | Grant or award | +3,800 | — | — |
| Aug 1, 2025 | Prime Medicine Inc. | Open-market purchase | +3,030,300 | $3.30 | $9,999,990 |
| Apr 2, 2024 | Boundless Bio Inc. | Derivative conversion | +589,743 | — | — |
| Apr 2, 2024 | Boundless Bio Inc. | Derivative conversion | +787,545 | — | — |
| Apr 2, 2024 | Boundless Bio Inc. | Derivative conversion | +1,048,433 | — | — |
| Apr 2, 2024 | Boundless Bio Inc. | Open-market purchase | +66,667 | $16.00 | $1,066,672 |
| Apr 2, 2024 | Boundless Bio Inc. | Open-market purchase | +133,333 | $16.00 | $2,133,328 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.